LifeMD, Inc. (NASDAQ:LFMD) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of LifeMD, Inc. (NASDAQ:LFMD) have been given an average rating of “Moderate Buy” by the ten ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $9.1429.

A number of research analysts have commented on the stock. Loop Capital set a $10.00 price objective on shares of LifeMD in a research note on Thursday, March 12th. Weiss Ratings upgraded shares of LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research note on Thursday, May 7th. Mizuho upgraded LifeMD from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $6.00 to $8.00 in a research report on Monday, March 16th. UBS Group reaffirmed a “buy” rating on shares of LifeMD in a research note on Wednesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of LifeMD in a research report on Tuesday, March 10th.

Institutional Investors Weigh In On LifeMD

Institutional investors and hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd acquired a new position in LifeMD during the fourth quarter worth $36,000. Magnus Financial Group LLC acquired a new stake in LifeMD in the fourth quarter valued at $41,000. R Squared Ltd acquired a new stake in LifeMD in the first quarter valued at $41,000. Jain Global LLC purchased a new position in shares of LifeMD in the fourth quarter valued at $45,000. Finally, Quarry LP purchased a new position in shares of LifeMD in the third quarter valued at $52,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

LifeMD News Summary

Here are the key news stories impacting LifeMD this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on LifeMD and maintained a $10.00 price objective, suggesting meaningful upside from current levels.
• Neutral Sentiment: The analyst still sees LifeMD posting a profit in some future periods, including Q4 2027 EPS of $0.15, which supports a longer-term recovery story.
• Negative Sentiment: HC Wainwright cut FY2026 EPS estimates to ($0.47) from ($0.33), signaling a more difficult profit outlook next year.
• Negative Sentiment: The firm also lowered Q2 2026 EPS estimates to ($0.24) from $0.06 and Q3 2026 EPS estimates to ($0.05) from $0.12, indicating weaker near-term earnings momentum.
• Negative Sentiment: Q4 2026 EPS estimates were also reduced to $0.02 from $0.18, suggesting that profitability may arrive later than previously expected.

LifeMD Trading Down 6.8%

Shares of LFMD opened at $4.28 on Friday. The firm has a market cap of $206.98 million, a PE ratio of 85.62 and a beta of 2.03. The company’s 50 day simple moving average is $4.17 and its 200-day simple moving average is $3.77. LifeMD has a 12-month low of $2.56 and a 12-month high of $15.84.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.06). The business had revenue of $50.16 million during the quarter, compared to analysts’ expectations of $48.84 million. LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. As a group, equities research analysts forecast that LifeMD will post -0.37 EPS for the current fiscal year.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.